Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

Additional locations may be listed on ClinicalTrials.gov for NCT04502394.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase I/II

Trial Typetreatment

Lead OrganizationKartos Therapeutics, Inc.

• Primary IDKRT-232-111
• Secondary IDsNCI-2021-00895
• ClinicalTrials.gov IDNCT04502394